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Abstract
Dynamic interactions between the gastrointestinal epithelium and the mucosal immune system normally
contribute to ensuring intestinal homeostasis and optimal immunosurveillance, but destabilisation of these
interactions in genetically predisposed individuals can lead to the development of chronic inflammatory diseases.
Ulcerative colitis is one of the main types of inflammatory diseases that affect the bowel, but its pathogenesis has
yet to be completely defined. Several genetic factors and other inflammation-related genes are implicated in
mediating the inflammation and development of the disease. Some susceptibility loci associated with increased risk
of ulcerative colitis are found to be implicated in mucosal barrier function. Different biomarkers that cause damage
to the colonic mucosa can be detected in patients, including perinuclear ANCA, which is also useful in
distinguishing ulcerative colitis from other colitides. The choice of treatment for ulcerative colitis depends on
disease severity. Therapeutic strategies include anti-tumour necrosis factor alpha (TNF-α) monoclonal antibodies
used to block the production of TNF-α that mediates intestinal tract inflammation, an anti-adhesion drug that
prevents lymphocyte infiltration from the blood into the inflamed gut, inhibitors of JAK1 and JAK3 that suppress
the innate immune cell signalling and interferons α/β which stimulate the production of anti-inflammatory
cytokines, as well as faecal microbiota transplantation. Although further research is still required to fully dissect the
pathophysiology of ulcerative colitis, understanding its cellular pathology and molecular mechanisms has already
proven beneficial and it has got the potential to identify further novel, effective targets for therapy and reduce the
burden of this chronic disease.
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The gastrointestinal (GI) tract, found in humans and an-
imals, represents a unique environment extending from
the mouth to the anus [1]. The intestine, a muscular
tube of the digestive system stretching from the stomach
to the anus, consists of the small and large intestine. It is
involved in food digestion as well as in enzyme and hor-
mone production (e.g. cholecystokinin that stimulates
the secretion of pancreatic enzymes and bile). It plays an
important role in fighting pathogens and in regulating
the body’s water balance [2] and it has been demon-
strated that the gut microflora potentially contributes to
proteolysis in the human colon [3]. The large intestine,
which is involved in the transport of water and electro-
lytes and the storage of faecal waste in the sigmoid colon
and rectum prior to elimination [1], is implicated in the
processing of indigestible food after most nutrients are
absorbed in the small intestine [4].
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Many disorders affect the colon’s ability to work prop-
erly. Inflammatory Bowel Disease (IBD) is a term used
to describe disorders that involve chronic inflammation
of the digestive tract, which include both ulcerative col-
itis (UC) and Crohn’s disease (CD), another chronic in-
flammatory disease that causes inflammation of the full
thickness of the bowel wall [5, 6]. Although strides are
being made in better understanding IBD, it is important
to shed light on its individual manifestations and for this
purpose, this article will focus on UC.
Ulcerative colitis and large intestine physiology
UC is a disease of unknown aetiology characterized by
inflammation of the mucosa and sub-mucosa of the
colon and rectum lining, causing ulcers to develop. It is
usually possible to notice a clear margin between normal
and affected intestinal tissue [7]. There has been a global
increase in UC incidence, with the highest incidence in
the West observed in Canada (16.7 per 100,000 people)
[8], while in Europe UC incidence ranges from 1.6 to
11.9 per 100,000 people, with more patients observed in
Northern European countries [9]. In the East, although
UC incidence is increasing, it is rarer with the greatest
incidence observed in Korea (3.62 per 100,000) [10].
Globally, due to its chronic nature and the low mortality
observed in UC, its prevalence has increased and can
reach up to 294 per 100,000 in Europe [11]. Certain
ethnic groups are more prone to UC, but environmental
factors, such as smoking, oral contraceptives, diet, anti-
biotics, vaccination, infections and childhood hygiene
also play a role [12]. UC may affect any age group, with
the peak age of diagnosis ranging from 15 to 40 years of
age and with most UC studies showing equal gender dis-
tribution [13]. UC often presents with blood in the stool
and diarrhoea. Common symptoms include urgency, in-
continence, fatigue, increased frequency of bowel move-
ments, mucus discharge, nocturnal defecations and
abdominal discomfort; fever and weight loss can also be
noticed. These clinical presentations may vary depending
on disease severity.
To dissect the molecular basis of UC, it is necessary to
have thorough knowledge of the cellular populations
that constitute the large intestine. The mucosa of the
colon is lined by a single-layered columnar epithelium
with a thin brush border that is essential for maintaining
gut homeostasis and functions as a physical and bio-
chemical barrier and a coordinating centre for immune
defense and crosstalk between bacteria and immune
cells. It consists of invaginations known as ‘crypts of
Lieberkühn’ (Fig. 1). Intestinal stem cells, which are re-
sponsible for the rapid renewal of the intestinal epithe-
lium, reside at the base of these crypts and develop into
transient proliferative cells that differentiate as they
travel through the transition zone, where intestinal
Fig. 1 The cross-sectional crypt structure of the large intestine and current UC therapeutic strategies. The intestinal epithelium is lined with a
single layer of polarized cells, whose major cell types include colonocytes, enteroendocrine, goblet cells and stem cells
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epithelial cells eventually shed into the lumen at the
apex of crypts [14]. Intestinal epithelial stem cells can
specialize into many cell types including enterocytes,
Paneth cells, goblet cells, and neuroendocrine cells [15].
Most of the cells present in the intestine are absorptive
cells, with the exception of crypt cells that are principally
secretory cells [2].
Colonocytes are the most abundant cell type in the
large intestine and they are involved in electrolyte ab-
sorption though passive diffusion of lipid-soluble
molecules [16]. Goblet and enteroendocrine cells are se-
cretive cells. Goblet cells are specialized epithelial cells,
which are found in the non-follicle bearing epithelium of
the intestine and they comprise around 10% of all intes-
tinal epithelial cells. They have an important role in in-
nate immunity by synthesizing and releasing mucin, a
viscous fluid enriched in mucin glycoproteins that form
large net-like polymers that lubricate the lumen to pro-
mote movement and effective diffusion of gut contents.
Goblet cells also act as a physical barrier, protecting the
intestinal wall from digestive enzymes and bacterial ad-
hesion to the underlining epithelium. Although goblet
cells are present in both the small and large intestine,
they are more abundant in the large intestine due to the
greater numbers of intestinal bacteria [17]. Goblet cells
also produce and secrete biologically active substances
that contribute to innate immunity, such as trefoil pep-
tides, resistin-like molecule β (RELMβ) and Fc-γ binding
protein (Fcgbp), which respectively function to promote
epithelial restitution, inhibit intestinal nematode chemo-
taxis and stabilize the mucous layer [18].
Enteroendocrine cells, which produce and secrete
hormones, consist of 1% of the large intestinal epithe-
lium [19]. One of these molecules is vasoactive intes-
tinal peptide (VIP), a peptide hormone that inhibits
gastrin release and acid secretion and stimulates water
and electrolyte secretion by the small and large intes-
tines. Because VIP plays an essential role in regulating
colonic mucosal integrity and epithelial barrier
homeostasis, alterations in VIP tissue concentration
are associated with increased colitis susceptibility [20].
Correct functioning of specialized intestinal epithelial
cells is essential to maintain intestinal homeostasis
and its dysfunction plays a central role in the patho-
genesis of several diseases, including UC [21]. A com-
mon histological pattern identified in UC is the
architectural distortion of the intestinal epithelium
characterised by the shortening and reduced branch-
ing of the crypts [22]. This microscopic change in
chronic UC can be detected in every biopsy fragment
from the diseased colon [23]. The lamina propria of
the large intestine also contains immune cells, includ-
ing macrophages, dendritic cells, plasma cells, and
lamina propria lymphocytes [24]. These immune cells
together with UC patients’ genetic predisposition play
a crucial role in UC progression.
Genetics and immunological response
involvement in UC
UC is a multifactorial disorder; genetic predisposition,
epithelial barrier defects, dysregulated immune re-
sponses and environmental factors play a role in its
pathogenesis. A recent meta-analysis of genome-wide as-
sociation studies (GWAS) has identified 163 IBD-
associated loci linked to both UC and CD. These loci
contain genes involved in autophagy, microbe recogni-
tion, lymphocyte signalling, response to endoplasmic
reticulum stress and cytokine signalling [25]. Although
the exact aetiology of UC remains elusive, the com-
mensal luminal flora is known to trigger an inappropri-
ate and overactive mucosal immune response in
genetically susceptible individuals, causing intestinal
tissue damage.
The meta-analysis of GWAS has found many novel
single nucleotide polymorphisms (SNPs) for UC, which
is believed to be more genetically heterogeneous than
CD. 163 risk loci have been identified, of which 110 con-
fer common susceptibility to IBD; hence, these SNPs are
associated with both disease phenotypes, whereas 30
seem to be specific to CD and 23 to UC [26]. These UC
SNPS are found in genes implicated in mucosal barrier
function, such as Extracellular Matrix 1 (ECM1),
Cadherin Type 1 (CDH1), Hepatocyte Nuclear Factor 4
alpha (HNF4α) and Laminin Beta 1 (LAMB1; Table 1).
Polymorphisms in Interleukin 10 (IL-10) correlate with
impaired IL-10 production that confers UC risk [27].
The majority of molecular differences between UC and
CD are found in human leukocyte antigen (HLA) Class
II genes and in genes associated with binding pattern
recognition [30]. These include nucleotide-binding
oligomerization domains (NODs) and toll-like receptors
(TLRs), innate immunity, (IL-23R) and autophagy path-
ways (ATG16L1, IRGM). HLA class II genes DR2, DR9,
and DRB1*0103, were shown to be UC susceptibility
genes, in fact, DRB1*0103 is significantly associated with
disease susceptibility, extensive disease and an increased
risk of colectomy [30]. On the other hand, the HLA class
II gene DR4 was a protective gene in UC [30].
In addition, Cytotoxic T-lymphocyte antigen 4
(CTLA4) is an inhibitory receptor expressed by activated
T cells and an important downregulator of T cell activa-
tion, as it suppresses T cell effector function following
initial activation by co-stimulatory signals [31]. CTLA4
plays a critical role in the priming phase of the immune
response and it might also contribute to peripheral toler-
ance. Because CTLA4 has an important role as a
negative regulator of T cell activation and monocyte-
macrophage cognate interaction, it is considered a good
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candidate gene for UC susceptibility. Several genetic poly-
morphisms have been reported in the human CTLA4 gene
[30]. One such study was performed on 87 Chinese UC
patients that were genotyped for CTLA-4 promoter − 1661
and A-1661G non-exonic region polymorphisms. It was
concluded that the A-1161G CTLA4 polymorphism is a
UC risk factor in Chinese patients [31].
Besides the genetic profile of UC patients, it is im-
portant to note that the disease itself involves dysregu-
lated immune responses against intraluminal and
mucosal antigens, which usually include commensal
bacteria [32]. It is believed that the chronic inflamma-
tory response arises following a pathogenic organism
infection such as Shigella spp. or Campylobacter spp.,
which remains in the intestinal tissues [33]. Exposure
to microbial peptides that share immunogenic elements
with self-antigens induces immune tolerance disruption
to endogenous gut antigens. Thus, a possible under-
lying basis for UC is a destructive inflammatory re-
sponse directed towards self-antigens such as mucin,
goblet cells and colonocytes [34].
Autoantibodies in the mucosa of the large intestine
may play a part in the pathogenesis of this disease. The
local production of these autoantibodies is stimulated by
T-cell abnormalities that reside within the epithelial cell
layer and the lamina propria of the large intestine and
the associated activation of antibody-producing cells
[35]. The autoantibodies detected in the serum of UC
patients include the anti-colon antibody and the anti-
neutrophil cytoplasmic antibody (ANCA) [35]. These are
involved in antibody-dependent cell-mediated cytotox-
icity (ADCC), which is presumed to be the cause of
damage that occurs to colonic mucosa [36]. Levels of
disease-specific autoantibodies to a neutrophil protein
with a perinuclear distribution, pANCA, reflect the
extent of the immune response associated with UC.
However, these antibodies may develop following an in-
fection; hence, there is not enough evidence to support
the correlation between these autoantibodies and the
pathogenesis of the disease [36].
One recurrent UC feature is neutrophil accumulation in
the inflamed intestinal mucosa. Neutrophil granulocytes
contain enzymes, one of which is myeloperoxidase
(MPO). This granule enzyme is released upon stimulation
with cytotoxic oxygen metabolites. Therefore, activated
neutrophils may contribute to tissue damage at sites of in-
flammation. It has been shown that MPO concentrations
were increased several fold in UC patients compared to
healthy controls, which is indicative of enhanced neutro-
phil activity [36]. Faecal MPO assessment is a simple,
non-invasive marker of disease and inflammation activity.
Low stool MPO levels can detect intestinal healing and it
is an early marker of treatment response in UC patients,
while high levels can predict relapse [36].
There is also considerable evidence that defective mu-
cosal immunoregulation, including abnormal changes of
T cells, B cells, granulocytes, macrophages and the cyto-
kines and chemokines produced by these cells, plays a
major role in UC pathogenesis [35]. One of the consist-
ently replicated markers found in UC patients is the
SNP rs3024505, which immediately flanks IL10 on
chromosome 1q32.1 [37]. Polymorphisms in IL-10 are
associated with loss-of-function mutations in IL-10 and
IL-10 receptor and are characteristic of early UC onset
[38]. IL10 is an immunosuppressive cytokine produced
by B cells, T cells, macrophages and some non-
haematopoietic cells upon stimulation [39]. IL-10 has a
broad effect in immunoregulation and host defense, as it
affects both the innate and adaptive immune systems
[40]. Macrophage-derived IL-10 was shown to be dis-
pensable for mouse gut homeostasis, while IL-10 recep-
tor deletion resulted in the manifestation of severe
colitis due to monocyte-derived macrophages impaire-
ment [41]. Pro-inflammatory cytokines that should be
suppressed by IL-10 can be regulated by nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB).
Abnormal activation of NF-κB and impaired production
of IL-10 have been proposed to influence UC patho-
physiology [42].
The role of biomarkers and treatment options in
UC
The variable immunological responses and complex gen-
etics of UC pose a significant problem to the clinical and
scientific community, with regards to identifying a suit-
able treatment strategy for all patients. A number of ap-
proaches have been attempted in the past decade and
various clinical trials are underway, in order to identify
Table 1 The genes implicated in mucosal barrier function that confer risk to UC [27–29]
GENE LOCUS SNP PROTEIN NAME FUNCITON
ECM1 1q21 rs3737240 Extracellular matrix protein 1 Glycoprotein involved in cell proliferation
CDH1 16q22 rs12597188 E-cadherin Protein involved in epithelial adherens junction
HNF4A 20q13 rs6017342 Hepatocyte nuclear factor 4α Transcriptional factor that regulates cellular differentiation along crypt-villus axis
LAMB1 7q31 rs886774 Laminin β1 Protein involved in cell adhesion and differentiation
IL10 1q32 rs3024505 Interleukin 10 Anti-inflammatory cytokine
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treatments that will allow all patients to quickly reach
and remain in remission after periods of flare-ups. A
uniform approach for all UC patients is however proving
quite challenging and as such, a tendency towards perso-
nalised treatment and care approaches is rapidly gaining
ground. Assisting towards this goal, the identification of
specific biomarkers could help predict UC’s course and
identify specific pathways involved in disease progression
and improved treatment [43, 44]. A known UC serum
diagnostic biomarker is pANCA, found in 50–75% of
UC patients. pANCA staining distinguishes UC from
CD and other colitides and provides a prognostic feature
of the risk of developing refractory pouchitis after colec-
tomy [45]. However, pANCA can also identify an anti-
gen expressed by bacteria resident in the human colonic
mucosa, therefore some bacterial proteins cross-react to
pANCA epitopes. It was observed that UC patients with
high pANCA titers, had higher anti-OmpC E.coli IgG
levels than healthy controls [36]. The cross-reactivity of
serum UC pANCA with E. coli membrane protein
OmpC, suggests that enteric bacterial proteins are in-
volved in UC pathogenesis [33]. It should be noted that
32% of healthy controls were tested positive for pANCA,
limiting the diagnostic value of this biomarker [44]. In
addition to biomarkers, an exponential increase in the
number of novel therapeutic UC targets has been ob-
served in the past decade, although it is interesting to
note that their efficiency varies in the UC patient popu-
lation, highlighting the need for personalised medicine
interventions. Infliximab, adalimumab and golimumab
are the anti-tumour necrosis factor alpha (TNF-α)
monoclonal antibodies available in the UK for the treat-
ment of UC in adults, but they can also be used to treat
other immune-mediated disorders such as rheumatoid
arthritis, ankylosing spondylitis, psoriasis, hidradenitis
suppurativa and refractory asthma [46]. TNF-α is an in-
flammatory cytokine produced by macrophages and
monocytes during acute inflammation and it is involved
in inflammation, apoptosis, stimulation of lymphocytes
and activation of immune cell functions [47]. TNF-α is
one of the most important cytokines that mediates intes-
tinal tract inflammation and increased TNF-α expression
is detected in UC patients [48]. Clinical trials showed
that treatment with TNF-α inhibitors results in a signifi-
cantly higher rate of clinical response, clinical remission
and mucosal healing in UC [48], nevertheless, although
TNF-α inhibitors are effective in a proportion of UC pa-
tients, their mechanisms of action in UC remain largely
unknown. Increased mononuclear phagocyte popula-
tions were observed in non-responder UC patients pre
and post-infliximab treatment [49], potentially shedding
some light into why UC patients, who initially respond
to infliximab treatment, lose response or become resist-
ant over time. Although data on the adverse effects of
infliximab in UC patients is limited, infectious complica-
tions such as bacterial pneumonia, tuberculosis and op-
portunistic infections can occur during therapy [48].
The adhesion of T lymphocytes from the peripheral
circulation to the gut mucosa is a central step for the
progression of the inflammatory process in UC [50]. Dif-
ferent anti-adhesion agents have been suggested for UC
treatment. Vedolizumab is a humanised monoclonal
IgG-1 antibody that selectively inhibits α4β7 integrin
and mucosal addressin cell adhesion molecule-1 (MAd-
CAM-1) interaction. It prevents lymphocyte infiltration
from the blood into the inflamed gut tissue, reducing
local inflammation [51]. In addition to this effect,
vedolizumab also reduces α4β7-dependent gut homing
of non-classical monocytes, resulting in a decrease in al-
ternatively activated M2-like macrophages in the gut
[52]. In contrast to other anti-adhesion drugs, the use of
vedolizumab in UC patients did not increase the rates of
opportunistic or enteric infections and there were no re-
ported cases of progressive multifocal leukoencephalopa-
thy [53]. Following encouraging results in randomized,
double-blind, placebo-controlled trials in the pivotal
phase III GEMINI studies, vedolizumab has been ap-
proved by US FDA for the treatment of adult patients
with active UC who had a poor response to standard
therapies [54]. Nevertheless, mononuclear phagocyte en-
richment was detected in non-responder UC patients be-
fore vedolizumab treatment, which further increased
post treatment [52], partly explaining why some UC pa-
tients do not respond as well to this drug.
Another important therapeutic target is the Janus kin-
ase (JAK) family of tyrosine kinases, which contains four
members JAK1, JAK2, JAK3 and TYK2 that are respon-
sible for mediating signal transduction for many cyto-
kine receptors including interleukins (ILs) 2, 4, 6, 7, 9,
12, 15 and 21 [55]. Tofacitinib is a novel selective inhibi-
tor of JAK1 and JAK3 and, to a lesser extent, JAK2 [56],
with Phase 3 trials showing a significant amelioration in
symptoms in moderate and severe UC patients [57]. This
oral drug works by suppressing the differentiation of
pathogenic Th1 and Th17 cells and innate immune cell
signalling and it was demonstrated to be efficient in in-
ducing and maintaining remission and achieving muco-
sal healing in patients with moderately to severely active
UC [57].
Different pilot clinical trials have evaluated the efficacy
of type I IFN-α and IFN-β (IFN-α/β) in active UC, deliv-
ering promising results. IFN-α/β is involved in stimulat-
ing the production of anti-inflammatory cytokine IL-10
by CD4+ T cells. IFN-α/β also plays a role in the modu-
lation of Th1 responses and it inhibits production of
Th2 cytokines, IL-5 and IL-13 that are upregulated in
the mucosa of UC patients [58]. However, the majority
of patients treated with IFN-α/β experienced adverse
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events such as headache, arthralgia, myalgia, abdominal
pain, fatigue and vomiting [59].
Another therapeutic intervention involves phospho-
lipids, the components of the GI mucus which they are
indispensable for intact barrier function [60]. Phosphat-
idylcholine (PC) is the major mucus phospholipid and
was significantly reduced in the mucus of UC patients
compared to healthy controls [61]. Lack of PC could en-
able the invasion of luminal noxious agents into the gut
mucosa [61]. Hence, there is the hypothesis that PC re-
constitution in the colonic mucus of UC patients could
help to re-establish the structure and density of the
mucus, enhance mucus barrier function and prevent ul-
terior inflammation in UC. Oral daily administration of
a PC-rich phospholipid preparation could be an innova-
tive therapeutic approach that helps with remission in
moderate UC patients, without the significant side ef-
fects that are usually seen with the usage of steroid or
immunosuppressive therapy [55].
Alternative therapies, such as probiotics (Escherichia
coli Nissle), can also be considered in preventing UC re-
lapse. Probiotics act as a barrier, as they line the intes-
tinal tract and through competitive inhibition, prevent
other luminal bacteria from reaching the lamina propria
and stimulating the mucosal immune system [62]. Pro-
biotics also enhance mucus production which protects
against invasive bacteria, induce protective cytokines and
suppress pro-inflammatory cytokines and can modulate
the immune system in the gut [63, 64]. In addition, fae-
cal microbiota transplantation (FMT), the transfer of
stool from a healthy donor to a UC patient is emerging
as a promising approach to alleviating UC severity. FMT
has been shown to result in increased secretory IgA and
mucin as well as anti-microbial peptide production,
affecting pathogen invasion by antigen/pathogen-
dependent and –independent targeting [65]. In the case
of UC, a few randomised controlled trials are currently
underway, with one recent study showing that some UC
patients could achieve remission following continuous
FMT thanks to the observed greater microbial diversity
and enrichment of Eubacterium hallii and Roseburia
inulivorans in faecal and colon samples [66]. Signifi-
cantly, the immunological outcomes of FMT are hard to
dissect. A randomised clinical trial failed to identify any
significant changes in γδ T cells, natural killer cell or
overall T cell ratios, although they discovered a slight in-
crease in gut-homing CD4 cells [67]. A study of moder-
ate to severe UC patients did not identify any changes in
serum cytokines (including IL-10 and IL-17) post single
upper GI FMT delivery [68], while another single FMT
study detected a reduction in colonic mucosal Th1 and
Treg cells post-FMT, but no difference in the Th17 cell
population [69]. It thus transpires that repeated FMT
might be necessary for successful UC remission and the
choice of donors with the appropriate microbiome might
prove beneficial in improving UC patient outcomes.
Conclusions
It becomes obvious from the above that the identification
of specific biomarkers and increased knowledge of the im-
munological and cellular mechanisms of the disease can
contribute to better understanding of UC pathogenesis.
Elevated mononuclear phagocyte populations in UC co-
lonic mucosa could partly explain why some UC patients
respond well to infliximab and vedolizumab treatment
and others do not. Although the above-mentioned drugs
and treatment strategies have been shown to be fairly ef-
fective, the next challenge would be to develop targeted
and personalised therapies for UC patients, potentially
also taking advantage of the genetic and cellular technol-
ogy advancements in IBD. It remains to be seen whether
these approaches will be effective for the wide spectrum of
UC patients, but the recent advances in personalised
medicine create endless opportunities for the future of UC
diagnosis and prognosis.
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